drugset / Trial / NCT00121615
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.
Timeline
- Start
- 2004-10
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 25 mg | — |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | — |